Relationship between serum IgG4 levels and clinical activity of ophthalmopathy in Graves’ disease

The aim of this study was to evaluate the association between serum IgG4 levels and the presence, activity, and severity of thyroid eye disease (TED) within a single cohort of patients with Graves’ disease, and to assess the potential role of IgG4 as a complementary biomarker across the clinical spectrum of the disease. This cross-sectional study included 46 patients diagnosed with Graves’ disease, comprising 23 patients with TED and 23 without TED. All participants underwent a comprehensive ophthalmological and biochemical evaluation, including thyroid function testing, autoantibody profiling, and measurement of serum total IgG, IgG4, and the IgG4/IgG ratio. Disease activity was assessed using the Clinical Activity Score (CAS ≥ 3), and disease severity was classified according to the European Group on Graves’ Orbitopathy (EUGOGO) criteria. Serum IgG4 levels were significantly higher in TED patients than in those without TED (97.7 ± 92.6 vs. 52.9 ± 42.9 mg/dL; p = 0.041). The IgG4/IgG ratio was also increased (8.05 ± 6.75% vs. 4.44 ± 3.42%; p = 0.027). Moderate-to-severe TED showed higher IgG4 and IgG4/IgG values than mild disease ( p = 0.042 and p = 0.041). Active TED had greater IgG4 levels than inactive cases (132.0 ± 112.1 vs. 60.2 ± 45.4 mg/dL; p = 0.049). IgG4 correlated positively with activity and severity. The proportion of patients with IgG4 ≥ 135 mg/dL was 8.7% in patients without TED and 21.7% in those with TED, with higher proportions particularly observed in active and moderate-to-severe cases. Elevated serum IgG4 levels in TED were associated with the presence, activity, and severity of the disease. These findings suggest that serum IgG4 may reflect underlying immunological activity across the TED spectrum. Measurement of serum IgG4 may serve as a complementary biomarker to conventional clinical scoring systems in the assessment of disease activity and severity. To clarify the clinical significance and temporal dynamics of these associations, large-scale prospective and longitudinal studies incorporating imaging and tissue-based evaluations are warranted.

Authors

Institutions

Publication Details

Journal
BMC Ophthalmology
Published
2026-09-04
DOI
https://doi.org/10.1186/s12886-026-05297-4
Primary Topic
IgG4-Related and Inflammatory Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Relationship between serum IgG4 levels and clinical activity of ophthalmopathy in Graves’ disease

Feyza Önder, Dogan Menges, Ahu Yılmaz, Özlem Doğan
BMC Ophthalmology
IgG4-Related and Inflammatory Diseases
article

Relationship between serum IgG4 levels and clinical activity of ophthalmopathy in Graves’ disease

Feyza Önder, Dogan Menges, Ahu Yılmaz, Özlem Doğan
article en

Abstract

The aim of this study was to evaluate the association between serum IgG4 levels and the presence, activity, and severity of thyroid eye disease (TED) within a single cohort of patients with Graves’ disease, and to assess the potential role of IgG4 as a complementary biomarker across the clinical spectrum of the disease. This cross-sectional study included 46 patients diagnosed with Graves’ disease, comprising 23 patients with TED and 23 without TED. All participants underwent a comprehensive ophthalmological and biochemical evaluation, including thyroid function testing, autoantibody profiling, and measurement of serum total IgG, IgG4, and the IgG4/IgG ratio. Disease activity was assessed using the Clinical Activity Score (CAS ≥ 3), and disease severity was classified according to the European Group on Graves’ Orbitopathy (EUGOGO) criteria. Serum IgG4 levels were significantly higher in TED patients than in those without TED (97.7 ± 92.6 vs. 52.9 ± 42.9 mg/dL; p = 0.041). The IgG4/IgG ratio was also increased (8.05 ± 6.75% vs. 4.44 ± 3.42%; p = 0.027). Moderate-to-severe TED showed higher IgG4 and IgG4/IgG values than mild disease ( p = 0.042 and p = 0.041). Active TED had greater IgG4 levels than inactive cases (132.0 ± 112.1 vs. 60.2 ± 45.4 mg/dL; p = 0.049). IgG4 correlated positively with activity and severity. The proportion of patients with IgG4 ≥ 135 mg/dL was 8.7% in patients without TED and 21.7% in those with TED, with higher proportions particularly observed in active and moderate-to-severe cases. Elevated serum IgG4 levels in TED were associated with the presence, activity, and severity of the disease. These findings suggest that serum IgG4 may reflect underlying immunological activity across the TED spectrum. Measurement of serum IgG4 may serve as a complementary biomarker to conventional clinical scoring systems in the assessment of disease activity and severity. To clarify the clinical significance and temporal dynamics of these associations, large-scale prospective and longitudinal studies incorporating imaging and tissue-based evaluations are warranted.

BMC Ophthalmology
State Hospital (GB), Sivas State Hospital (TR), Haseki Eğitim ve Araştırma Hastanesi (TR), Istanbul Eye Hospital (TR)
Openalex Percentile: Top 10%
IgG4-Related and Inflammatory Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.